GlassScriptPhysician profile
Michael T Stewart
NPI 1184611493
$5,319.02
in general payments reported to CMS, 2019-2025
27 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $333 · 2021: $597 · 2022: $878 · 2023: $1,110 · 2024: $1,047 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,113.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $644.21 | 2020-2025 | |
| Novo Nordisk INC | $605.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $588.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $402.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $366.78 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $304.07 | 2024-2025 | |
| Abbvie INC. | $279.60 | 2021-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $241.74 | 2021-2024 | Rexulti |
| Exact Sciences Corporation | $136.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $116.38 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $96.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $67.50 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.29 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $43.21 | 2019-2023 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.92 | 2024-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $32.92 | 2025 | Voquezna |
| Almatica Pharma LLC | $28.81 | 2021 | |
| Astellas Pharma US INC | $28.62 | 2025 | Veozah |
| Tosoh Bioscience, INC. | $22.51 | 2021 | |
| Abbott Laboratories | $18.20 | 2019 | |
| Shire North American Group INC | $16.99 | 2019 | |
| Lundbeck LLC | $16.27 | 2024 | Rexulti |
| Mylan Specialty L.P. | $15.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.21 | 2023 | Livalo |
| Sanofi-Aventis U.S. LLC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.